After introducing the session by presenting a clinical case, Prof Volterrani highlights the fact that we are currently experiencing a major shift in clinical recommendations based on the personalized treatment approach: The place for Heart Rate reducing agent is clear in this new approach.

Also, the synergy between BB and Ivabradine is now well established and real experience shows the importance of early introduction of Ivabradine.

Finally, he underlines that clinical experience shows that the introduction of neutral agents on blood pressure such as Ivabradine can be a tool to maximize the use of other therapies.